Discussion led by:
Mark Albers, MD, PhD
Associate Professor of Neurology, Harvard Medical School;
Frank Wilkens Jr and Family Endowed Chair in Alzheimer’s Disease Research, Massachusetts General Hospital

Dr. Mark Albers of the Harvard Program in Therapeutic Science and the Program in Neuroscience will interview James Carney, one of his patients from his Memory Clinic at MGH that he has followed for many years and discuss new approaches to quantify functional, cellular, and molecular biomarkers of neurodegenerative disease in living patients with neurodegenerative diseases, including Alzheimer’s disease and ALS. Mr. Carney was the first patient at MGH to receive a life saving treatment of mastoidistis when he was young, the first person to receive a clinical amyloid PET scan at MGH, and is one of the first participants in a new nasal brushing study for biomarker discovery at MGH and Harvard Medical School.

This series features clinicians and patients discussing the lived experience of people with neurological and psychiatric disorders. We hope to spark conversations on the human impact of basic science research & inspire new patient-centered research ideas.

In First-Person is organized by:
Akshay Jaggi (akshay_jaggi@hms.harvard.edu)
Jill Jones (jilljones@hms.harvard.edu)
Sophia Renauld (sophia_renauld@hms.harvard.edu)